386 related articles for article (PubMed ID: 18424820)
1. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet in hyperfunctioning parathyroid diseases.
Imanishi Y; Inaba M; Kawata T; Nishizawa Y
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
[TBL] [Abstract][Full Text] [Related]
4. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
[TBL] [Abstract][Full Text] [Related]
5. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
9. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism.
Malberti F; Farina M; Imbasciati E
Nephrol Dial Transplant; 1999 Oct; 14(10):2398-406. PubMed ID: 10528664
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
Nemeth EF; Heaton WH; Miller M; Fox J; Balandrin MF; Van Wagenen BC; Colloton M; Karbon W; Scherrer J; Shatzen E; Rishton G; Scully S; Qi M; Harris R; Lacey D; Martin D
J Pharmacol Exp Ther; 2004 Feb; 308(2):627-35. PubMed ID: 14593085
[TBL] [Abstract][Full Text] [Related]
12. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
[TBL] [Abstract][Full Text] [Related]
13. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet reduces the set point of the PTH-calcium curve.
Valle C; Rodriguez M; Santamaría R; Almaden Y; Rodriguez ME; Cañadillas S; Martin-Malo A; Aljama P
J Am Soc Nephrol; 2008 Dec; 19(12):2430-6. PubMed ID: 18632847
[TBL] [Abstract][Full Text] [Related]
15. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
Schwarz A; Merkel S; Leitolf H; Haller H
Transplantation; 2011 Mar; 91(5):560-5. PubMed ID: 21192318
[TBL] [Abstract][Full Text] [Related]
16. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient.
Komaba H; Shin J; Fukagawa M
Nephrol Dial Transplant; 2010 Feb; 25(2):638-41. PubMed ID: 19892751
[TBL] [Abstract][Full Text] [Related]
17. The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve.
Bas S; Aguilera-Tejero E; Bas A; Estepa JC; Lopez I; Madueño JA; Rodriguez M
J Endocrinol; 2005 Jan; 184(1):241-7. PubMed ID: 15642800
[TBL] [Abstract][Full Text] [Related]
18. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism.
Cetani F; Picone A; Cerrai P; Vignali E; Borsari S; Pardi E; Viacava P; Naccarato AG; Miccoli P; Kifor O; Brown EM; Pinchera A; Marcocci C
J Clin Endocrinol Metab; 2000 Dec; 85(12):4789-94. PubMed ID: 11134144
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet for the treatment of primary hyperparathyroidism.
Sajid-Crockett S; Singer FR; Hershman JM
Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
